DETAILED NOTES ON ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURERS

Such carryover shouldn't result in the carryover of degradants or microbial contamination which will adversely alter the set up API impurity profile.The controls Utilized in the manufacture of APIs for use in clinical trials must be in line with the stage of progress with the drug products incorporating the API. Process and test processes ought to